183 related articles for article (PubMed ID: 32670545)
1. Genome editing of CCR5 by AsCpf1 renders CD4
Liu Z; Liang J; Chen S; Wang K; Liu X; Liu B; Xia Y; Guo M; Zhang X; Sun G; Tian G
Cell Biosci; 2020; 10():85. PubMed ID: 32670545
[TBL] [Abstract][Full Text] [Related]
2. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
[TBL] [Abstract][Full Text] [Related]
3. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
Cell Biosci; 2017; 7():47. PubMed ID: 28904745
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
[TBL] [Abstract][Full Text] [Related]
6. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.
Wang W; Ye C; Liu J; Zhang D; Kimata JT; Zhou P
PLoS One; 2014; 9(12):e115987. PubMed ID: 25541967
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
8. Inducing CCR5Δ32/Δ32 Homozygotes in the Human Jurkat CD4+ Cell Line and Primary CD4+ Cells by CRISPR-Cas9 Genome-Editing Technology.
Qi C; Li D; Jiang X; Jia X; Lu L; Wang Y; Sun J; Shao Y; Wei M
Mol Ther Nucleic Acids; 2018 Sep; 12():267-274. PubMed ID: 30195765
[TBL] [Abstract][Full Text] [Related]
9. CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus.
Kang H; Minder P; Park MA; Mesquitta WT; Torbett BE; Slukvin II
Mol Ther Nucleic Acids; 2015 Dec; 4():e268. PubMed ID: 26670276
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice.
Li S; Holguin L; Burnett JC
Mol Ther Methods Clin Dev; 2022 Mar; 24():321-331. PubMed ID: 35229006
[TBL] [Abstract][Full Text] [Related]
11. Efficient genome editing in wheat using Cas9 and Cpf1 (AsCpf1 and LbCpf1) nucleases.
Kim D; Hager M; Brant E; Budak H
Funct Integr Genomics; 2021 Jul; 21(3-4):355-366. PubMed ID: 33710467
[TBL] [Abstract][Full Text] [Related]
12.
Xu M
Cell Biosci; 2020; 10():48. PubMed ID: 32257106
[TBL] [Abstract][Full Text] [Related]
13. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.
Wang Q; Chen S; Xiao Q; Liu Z; Liu S; Hou P; Zhou L; Hou W; Ho W; Li C; Wu L; Guo D
Retrovirology; 2017 Nov; 14(1):51. PubMed ID: 29141633
[TBL] [Abstract][Full Text] [Related]
14. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
[TBL] [Abstract][Full Text] [Related]
15. Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1.
Badia R; Riveira-Muñoz E; Clotet B; Esté JA; Ballana E
J Antimicrob Chemother; 2014 Jul; 69(7):1755-9. PubMed ID: 24651827
[TBL] [Abstract][Full Text] [Related]
16. Biallelic, Selectable, Knock-in Targeting of CCR5
Scheller SH; Rashad Y; Saleh FM; Willingham KA; Reilich A; Lin D; Izadpanah R; Alt EU; Braun SE
Front Immunol; 2022; 13():821190. PubMed ID: 35386712
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the editing patterns and editing efficiencies of TALEN and CRISPR-Cas9 when targeting the human CCR5 gene.
Nerys-Junior A; Braga-Dias LP; Pezzuto P; Cotta-de-Almeida V; Tanuri A
Genet Mol Biol; 2018; 41(1):167-179. PubMed ID: 29583154
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV-1 Infection.
Romito M; Juillerat A; Kok YL; Hildenbeutel M; Rhiel M; Andrieux G; Geiger J; Rudolph C; Mussolino C; Duclert A; Metzner KJ; Duchateau P; Cathomen T; Cornu TI
Biotechnol J; 2021 Jan; 16(1):e2000023. PubMed ID: 33103367
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cpf1 enables fast and simple genome editing of Saccharomyces cerevisiae.
Verwaal R; Buiting-Wiessenhaan N; Dalhuijsen S; Roubos JA
Yeast; 2018 Feb; 35(2):201-211. PubMed ID: 28886218
[TBL] [Abstract][Full Text] [Related]
20. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5.
Mock U; Machowicz R; Hauber I; Horn S; Abramowski P; Berdien B; Hauber J; Fehse B
Nucleic Acids Res; 2015 Jun; 43(11):5560-71. PubMed ID: 25964300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
